Trial Profile
A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children With Refractory or Recurrent Solid Tumors
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs SGT 53 (Primary) ; Cyclophosphamide; Topotecan
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors SynerGene Therapeutics
- 07 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 07 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 07 Feb 2022 Status changed from active, no longer recruiting to suspended.